| 800858 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial |
2022-02-01 |
10.1136/jitc-2021-003027 |
West Howard Jack, McCleland Mark, Cappuzzo Federico, Reck Martin, Mok Tony SK, Jotte Robert M, Nishio Makoto, Kim Eugene, Morris Stefanie, Zou Wei, Shames David, Das Thakur Meghna, Shankar Geetha, Socinski Mark A |
| 800857 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Correction: Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver? |
2022-02-01 |
10.1136/jitc-2021-002820corr1 |
|
| 800856 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells |
2022-02-01 |
10.1136/jitc-2021-003804 |
Clara Joseph Andrew, Levy Emily R, Reger Robert, Barisic Stefan, Chen Long, Cherkasova Elena, Chakraborty Mala, Allan David S J, Childs Richard |
| 800855 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers |
2022-02-01 |
10.1136/jitc-2021-004012 |
Duchemann Boris, Naigeon Marie, Auclin Edouard, Ferrara Roberto, Cassard Lydie, Jouniaux Jean-Mehdi, Boselli Lisa, Grivel Jonathan, Desnoyer Aude, Danlos François-Xavier, Mezquita Laura, Caramella Caroline, Marabelle Aurelien, Besse Benjamin, Chaput Nathalie |
| 800854 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner |
2022-02-01 |
10.1136/jitc-2021-003382 |
Thakkar Dipti, Paliwal Shalini, Dharmadhikari Bhushan, Guan Siyu, Liu Lillian, Kar Shreya, Tulsian Nikhil K, Gruber Joshua J, DiMascio Leah, Paszkiewicz Konrad H, Ingram Piers J, D Boyd-Kirkup Jerome |
| 800853 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Soluble PD-L1 as an early marker of progressive disease on nivolumab |
2022-02-01 |
10.1136/jitc-2021-003527 |
Mahoney Kathleen M, Ross-Macdonald Petra, Yuan Long, Song Linan, Veras Eliseo, Wind-Rotolo Megan, McDermott David F, Stephen Hodi F, Choueiri Toni K, Freeman Gordon J |
| 800852 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer |
2022-02-01 |
10.1136/jitc-2021-003731 |
Maeda Shingo, Motegi Tomoki, Iio Aki, Kaji Kenjiro, Goto-Koshino Yuko, Eto Shotaro, Ikeda Namiko, Nakagawa Takayuki, Nishimura Ryohei, Yonezawa Tomohiro, Momoi Yasuyuki |
| 800851 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy |
2022-02-01 |
10.1136/jitc-2021-004089 |
Augustin Ryan C., Leone Robert D., Naing Aung, Fong Lawrence, Bao Riyue, Luke Jason J. |
| 800850 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer |
2022-02-01 |
10.1136/jitc-2021-003465 |
Busenhart Philipp, Montalban-Arques Ana, Katkeviciute Egle, Morsy Yasser, Van Passen Chiara, Hering Larissa, Atrott Kirstin, Lang Silvia, Garzon Jesus Francisco Glaus, Naschberger Elisabeth, Hartmann Arndt, Rogler Gerhard, Stürzl Michael, Spalinger Marianne Rebecca, Scharl Michael |
| 800849 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Exosomes derived from γδ-T cells synergize with radiotherapy and preserve antitumor activities against nasopharyngeal carcinoma in immunosuppressive microenvironment |
2022-02-01 |
10.1136/jitc-2021-003832 |
Wang Xiwei, Zhang Yanmei, Mu Xiaofeng, Tu Chloe Ran, Chung Yuet, Tsao Sai Wah, Chan Godfrey Chi-Fung, Leung Wing-Hang, Lau Yu-lung, Liu Yinping, Tu Wenwei |
